Lipocine registers Phase 3 study of oral LPCN 1154A for postpartum depression
New trial testing Lipocine's oral brexanolone tablet against placebo in women with severe postpartum depression was listed on ClinicalTrials.gov.
Lipocine had one new registry entry posted this week.
- Lipocine registered a Phase 3 trial called "BLOOM" (NCT07822321) testing oral LPCN 1154A tablets, also described as brexanolone, against placebo in women with postpartum depression. The study is designed to determine if LPCN 1154A reduces depressive symptoms in subjects with severe PPD and how well the drug is tolerated.1 The trial plans to enroll 120 participants, with recruiting status listed as of the September 16, 2026 posting date, and an estimated primary completion in August 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.